ASP Calculation Rankles IG; Drugs To Face Dropping Reimbursement Rates?
Executive Summary
The HHS Office of Inspector General is dissatisfied with the CMS' response to an OIG report showing that comparison of a Part B-reimbursed drug's average sales price (ASP) with its average manufacturer price (AMP) yields different results based on the calculation method used